JOHNSON & JOHNSON is 115.4x more valuable than LIGAND PHARMACEUTICALS INC by market capitalization ($574.10 B vs $4.97 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | LGND | JNJ |
|---|---|---|
| Market cap | $4.97 B | $574.10 B |
| US-listed rank | #1389 | #20 |
| Revenue (latest FY) | $268.09M | $94.19B |
| Net income (latest FY) | $124.45M | $26.80B |
| Net margin | 46.4% | 28.5% |
| P/E (trailing FY) | 40.0 | 21.4 |
| SEC filings | 2,226 | 984 |
JOHNSON & JOHNSON is 115.4x more valuable than LIGAND PHARMACEUTICALS INC by market capitalization ($574.10 B vs $4.97 B).
In their latest fiscal years, LIGAND PHARMACEUTICALS INC reported $268.09M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: LIGAND PHARMACEUTICALS INC and JOHNSON & JOHNSON, or browse the full rankings.